Skip to main content
. Author manuscript; available in PMC: 2019 Oct 20.
Published in final edited form as: Eur J Haematol. 2018 Apr 20:10.1111/ejh.13083. doi: 10.1111/ejh.13083

Table 1.

Populations-based studies on trends in relative survival in multiple myeloma

Reference Study
period
Survival trend1 Note
Kristinsson 2007 1973–2003 5-year rel survival from 31 % to 36 %. Improvement only inpatients 60 years or younger Swedish Cancer Registry
Brenner 2008 1990–2004 5-year relative survival from 28.8% to 34.7%. Improvement mainly in patients 60 years or younger SEER database
Waxman 2010 1973–2005 5-year rel survival from 26.3% to 35.0% in whites. No significant improvement in blacks. SEER database
Turesson 2010 1960–2005 Median OS from 24.3 to 56.3 months in patients 65 years or younger. No significant change in those 66 years or older Information on treatment in individual patients City of Malmö Sweden
Renshaw 2010 1990–2004 5-year relative survival from 36 % to 47% in men and from 40 % to 56% in women. Thames Cancer Registry database UK
Shaapveld 2010 1989–2005 5-year relative survival from 34 % to 56% in patients < 65 years. No improvement in those 66 years or older. Two regional cancer centers the Netherlands
Pulte 2011 1973–2007 5-year relative survival from 32.8% to 40.3%. 10-year relative survival from 6.4% to 8.4% in patients 75 year or older SEER database
Pozzi 2013 1988–2009 5-year relative survival increased from 45.7% to 55.7 %. No significant improvement in patients > 75 years Modena Cancer Registry
Sant 2014 1997–2008 5-year relative survival increased from 29.8 % to 39.6 %. No significant improvement in patients > 75 years EUROCARE-5 database
Kristinsson 2014 1973–2009 5-year myeloma-specific survival from 36% to 68 % in patients 50 years or younger, from 34% to 58% in age cohort 51–65, from 26% to 41 % in age cohort 66–79. Disease-specific survival SEER database
Pulte 2015 2002–2010 5-year relative survival from 47.3% to 53.8% (Germany) and from 39.8% to 54,2% (US) Patients 75 years or older excluded SEER database and Germany
Rios-Tamayos 2015 1985–2009 Median OS from 17.7 months to 34 months. Improvement restricted to younger patients. Granada Cancer Registry Spain
Chihara 2015 1993–2006 No change in 5-year relative survival – from 30.0% to 27.8 %. 6 prefectures in Japan covering 13.4% of the Japanese population. Thalidomide, bortezomib and lenalidomide not approved during the study period.
Jansen 2015 2002–2010 5-year relative survival increased from 39,9% to 47,9 % 11 population-based cancer registries in Germany
Costa 2017 1993–2012 5-year relative survival from 36.3% to 61.8% in patients < 65 years, from 29.0% to 48.5% in age cohort 65–74 years and from 21.1% to 34.0% in age cohort 75 years or older. SEER database
Blimark 2017 2008–2014 5-year relative survival increased from 47.3 % to 51.3 % Swedish Myeloma Registry
Thorsteinsdottir 2018 1973–2013 5-year relative survival increased from 28% to 41% Swedish Cancer Registry
1

Comparison of survival for patients diagnosed in the first vs the last calendar period in each study.

2

Two studies that reported observed survival and one study reporting myeloma-specific survival included.